In Johnson & Johnson’s long-running talc litigation, a court-appointed special master has recommended that plaintiffs should be able to present testimony from expert witnesses who can speak to scientific evidence backing their claims. The decision could negatively impact the company’s
read more
More than 71% of patients treated with Unloxcyt achieved disease control More: Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma Source: News
read moreLed by cancer standout Darzalex, Johnson & Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its
read moreThe company announced a phase 3 win in the rare neurodegenerative disease Ataxia-Telangiectasia on the same day it snagged a key European approval in the drug’s original indication of Niemann-Pick disease type C. More: IntraBio's Aqneursa, on a roll with
read moreWhile much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizer’s CEO cut to the chase this week in a
read more© 1994 - 2026 B.M. Pharmaceuticals